Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Combined With Chemoradiotherapy in Pancreatic Cancer
NCT07386704Phase 2Enrolling by invitation
- Sponsor
- Peking University First Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in pancreatic cancer (PC), sponsored by Peking University First Hospital. Started Dec 2025; status: enrolling by invitation.
02
Drugs
nimotuzumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07386704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07386704.